Independent directory Public ClinicalTrials.gov records United States
Clinical Trials Finder
Objective public record navigation
Search Results

Search by objective public record fields.

Search by query text, NCT ID, condition, intervention, sponsor, city, state, recruitment status, phase, study type, healthy volunteer eligibility, sex, or age. Results are retrieved from ClinicalTrials.gov and synchronized into the directory. Search pages remain noindex by default.

Clear filters
ClinicalTrials.gov public records Last synced Sep 2, 2026, 7:17 AM EDT

Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.

Showing 1–24 of 39 matching trials from the live ClinicalTrials.gov search.
Local D1 index available.
Filters: Intervention: Acamprosate calcium Clear all
Recruiting Phase 4 Interventional

Temporally-Resolved Electrophysiology of Acamprosate Treatment of Alcohol Use Disorder

NCT06269627
View directory record Official record
Conditions
Alcohol Use Disorder
Interventions
Acamprosate calcium, Placebo
Drug · Other
Lead sponsor
National Institute on Alcohol Abuse and Alcoholism (NIAAA)
NIH
Eligibility
21 Years to 65 Years
Enrollment
48 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2025 – 2026
U.S. locations
1
States / cities
Bethesda, Maryland
Source: ClinicalTrials.gov public record
Updated Jul 21, 2026 · Synced Sep 2, 2026, 7:17 AM EDT
Completed Phase 4 Interventional Results available

Acamprosate in Alcoholics With Comorbid Anxiety or Depression

NCT00330174
View directory record Official record
Conditions
Alcohol Dependence, Major Depression, Social Anxiety Disorder, Generalized Anxiety Disorder
Interventions
Acamprosate
Drug
Lead sponsor
Medical University of South Carolina
Other
Eligibility
18 Years to 60 Years
Enrollment
90 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2006 – 2010
U.S. locations
3
States / cities
Belmont, Massachusetts • New York, New York • Pickens, South Carolina
Source: ClinicalTrials.gov public record
Updated Apr 12, 2015 · Synced Sep 2, 2026, 7:17 AM EDT
Completed Phase 3 Interventional

COMBINE (Acamprosate/Naltrexone)

NCT00006206
View directory record Official record
Conditions
Alcoholism
Interventions
naltrexone (Revia), acamprosate (Campral)
Drug
Lead sponsor
University of North Carolina, Chapel Hill
Other
Eligibility
18 Years and older
Enrollment
1,375 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
1997 – 2006
U.S. locations
12
States / cities
New Haven, Connecticut • Miami, Florida • Belmont, Massachusetts + 8 more
Source: ClinicalTrials.gov public record
Updated May 2, 2010 · Synced Sep 2, 2026, 7:17 AM EDT
Withdrawn Phase 2 Interventional

A Trial Evaluating the Efficacy, Safety, and Pharmacokinetics of SNC-102 in Subjects With Tourette Syndrome

NCT02217007
View directory record Official record
Conditions
Tourette Syndrome
Interventions
SNC-102 sustained release tablet
Drug
Lead sponsor
Synchroneuron Inc.
Industry
Eligibility
18 Years to 75 Years
Healthy volunteers
Healthy volunteers not accepted
Timeline
2015 – 2016
U.S. locations
2
States / cities
Chicago, Illinois • Manhasset, New York
Source: ClinicalTrials.gov public record
Updated Apr 12, 2021 · Synced Sep 2, 2026, 7:17 AM EDT
Completed Early Phase 1 Interventional Results available

Neurophysiological and Acute Pharmacological Studies in FXS Patients

NCT02998151
View directory record Official record
Conditions
Fragile X Syndrome
Interventions
Acamprosate, Lovastatin, Minocycline, Placebo, Baclofen
Drug
Lead sponsor
Children's Hospital Medical Center, Cincinnati
Other
Eligibility
15 Years to 55 Years
Enrollment
29 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2016 – 2020
U.S. locations
1
States / cities
Cincinnati, Ohio
Source: ClinicalTrials.gov public record
Updated Nov 25, 2021 · Synced Sep 2, 2026, 7:17 AM EDT
Completed Phase 2 Interventional Accepts healthy volunteers Results available

Acamprosate to Reduce Symptoms of Alcohol Withdrawal

NCT00106106
View directory record Official record
Conditions
Alcohol-Related Disorders, Alcohol Dependence, Alcoholism, Healthy Volunteer
Interventions
NMR-spectroscopy, Oral acamprosate
Procedure · Drug
Lead sponsor
National Institutes of Health Clinical Center (CC)
NIH
Eligibility
21 Years to 65 Years
Enrollment
56 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2005 – 2010
U.S. locations
1
States / cities
Bethesda, Maryland
Source: ClinicalTrials.gov public record
Updated Jan 11, 2012 · Synced Sep 2, 2026, 7:17 AM EDT
Completed Phase 3 Interventional Results available

Treatment With Acamprosate in Patients With Schizophrenia and Comorbid Alcoholism

NCT00463346
View directory record Official record
Conditions
Alcohol Dependence, Schizophrenia
Interventions
Acamprosate, Placebo
Drug
Lead sponsor
Yale University
Other
Eligibility
21 Years to 65 Years
Enrollment
23 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2006 – 2015
U.S. locations
1
States / cities
West Haven, Connecticut
Source: ClinicalTrials.gov public record
Updated Mar 30, 2020 · Synced Sep 2, 2026, 7:17 AM EDT
Withdrawn Phase 4 Interventional

Safety of Acamprosate for Alcohol Dependence in the Elderly: An Open-Label Study (SAFADIE)

NCT00655967
View directory record Official record
Conditions
Alcohol Dependence
Interventions
Acamprosate (Campral), Acamprosate
Drug
Lead sponsor
University of New Mexico
Other
Eligibility
60 Years and older
Healthy volunteers
Healthy volunteers not accepted
Timeline
2006
U.S. locations
1
States / cities
Albuquerque, New Mexico
Source: ClinicalTrials.gov public record
Updated Jul 31, 2023 · Synced Sep 2, 2026, 7:17 AM EDT
Terminated Not applicable Interventional

Study of Acamprosate in Driving Under the Influence (DUI) Court Participants

NCT00425711
View directory record Official record
Conditions
Alcohol Dependence
Interventions
Acamprosate
Drug
Lead sponsor
University of Oklahoma
Other
Eligibility
18 Years to 64 Years
Enrollment
4 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2007 – 2009
U.S. locations
1
States / cities
Tulsa, Oklahoma
Source: ClinicalTrials.gov public record
Updated Apr 5, 2026 · Synced Sep 2, 2026, 7:17 AM EDT
Withdrawn Phase 2 Interventional

A Phase 2 Trial Evaluating SNC-102 in Drug-Induced Tardive Dyskinesia

NCT02064010
View directory record Official record
Conditions
Drug-induced Tardive Dyskinesia
Interventions
SNC-102, Placebo
Drug
Lead sponsor
Synchroneuron Inc.
Industry
Eligibility
18 Years to 75 Years
Healthy volunteers
Healthy volunteers not accepted
Timeline
2014 – 2015
U.S. locations
1
States / cities
Los Angeles, California
Source: ClinicalTrials.gov public record
Updated Apr 12, 2021 · Synced Sep 2, 2026, 7:17 AM EDT
Terminated Phase 4 Interventional Results available

Study of Acamprosate to Prevent Alcohol Relapse in Criminal Justice Supervisees

NCT00249379
View directory record Official record
Conditions
Alcohol Dependence
Interventions
Acamprosate
Drug
Lead sponsor
Virginia Commonwealth University
Other
Eligibility
18 Years and older
Enrollment
26 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2005 – 2008
U.S. locations
1
States / cities
Richmond, Virginia
Source: ClinicalTrials.gov public record
Updated May 10, 2016 · Synced Sep 2, 2026, 7:17 AM EDT
Completed Phase 4 Interventional Results available

Acamprosate vs. Placebo in Bipolar Alcoholics

NCT00466661
View directory record Official record
Conditions
Alcohol Dependence, Bipolar Disorder
Interventions
Acamprosate, Placebo
Drug
Lead sponsor
Medical University of South Carolina
Other
Eligibility
18 Years to 65 Years
Enrollment
33 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2007 – 2010
U.S. locations
1
States / cities
Charleston, South Carolina
Source: ClinicalTrials.gov public record
Updated Dec 13, 2018 · Synced Sep 2, 2026, 7:17 AM EDT
Completed Phase 1 Interventional Accepts healthy volunteers

Study of Acamprosate in Fragile x Syndrome

NCT01911455
View directory record Official record
Conditions
Fragile X Syndrome
Interventions
acamprosate, Placebo
Drug
Lead sponsor
Children's Hospital Medical Center, Cincinnati
Other
Eligibility
5 Years to 23 Years
Enrollment
46 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2013 – 2018
U.S. locations
2
States / cities
Chicago, Illinois • Cincinnati, Ohio
Source: ClinicalTrials.gov public record
Updated Feb 2, 2021 · Synced Sep 2, 2026, 7:17 AM EDT
Not yet recruiting Not applicable Interventional

A Digital Pill System to Measure and Support Acamprosate Adherence in Individuals With Alcohol Associated Liver Disease

NCT07553377
View directory record Official record
Conditions
Alcohol Use Disorder, Alcohol Associated Liver Disease, Medications for Alcohol Use Disorder, Behavioral Medicine, Medication Adherence
Interventions
AcamproSync
Device
Lead sponsor
Yale University
Other
Eligibility
18 Years and older
Enrollment
50 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2027 – 2030
U.S. locations
1
States / cities
New Haven, Connecticut
Source: ClinicalTrials.gov public record
Updated Apr 27, 2026 · Synced Sep 2, 2026, 7:17 AM EDT
Completed Phase 1 Interventional

Clinical Trial of Acamprosate for Tinnitus

NCT00596531
View directory record Official record
Conditions
Tinnitus
Interventions
Acamprosate, Placebo
Drug
Lead sponsor
Oregon Health and Science University
Other
Eligibility
18 Years to 75 Years
Enrollment
154 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2008 – 2013
U.S. locations
1
States / cities
Portland, Oregon
Source: ClinicalTrials.gov public record
Updated Nov 7, 2016 · Synced Sep 2, 2026, 7:17 AM EDT
Withdrawn Phase 2 Interventional Accepts healthy volunteers

Acamprosate and Methazolamide for Essential Tremor

NCT06312800
View directory record Official record
Conditions
Essential Tremor
Interventions
Acamprosate, Placebo, Methazolamide
Drug
Lead sponsor
Henry Ford Health System
Other
Eligibility
18 Years to 70 Years
Healthy volunteers
Accepts healthy volunteers
Timeline
2016 – 2017
U.S. locations
1
States / cities
West Bloomfield, Michigan
Source: ClinicalTrials.gov public record
Updated Sep 24, 2024 · Synced Sep 2, 2026, 7:17 AM EDT
Completed Phase 2 Interventional Results available

Modulation of Pharmacologically Induced Alcohol Craving in Recently Detoxified Alcoholics

NCT00605904
View directory record Official record
Conditions
Alcoholism
Interventions
Acamprosate, Yohimbine, mCPP, Saline
Drug
Lead sponsor
National Institute on Alcohol Abuse and Alcoholism (NIAAA)
NIH
Eligibility
21 Years to 65 Years
Enrollment
37 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2008 – 2011
U.S. locations
1
States / cities
Bethesda, Maryland
Source: ClinicalTrials.gov public record
Updated Jul 2, 2012 · Synced Sep 2, 2026, 7:17 AM EDT
Recruiting Not applicable Interventional

Combining a Smartphone App With Medications to Manage Heavy Drinking

NCT06303778
View directory record Official record
Conditions
Alcohol Use Disorder (AUD)
Interventions
Stand Down mobile app, Standard Care
Other
Lead sponsor
VA Office of Research and Development
Federal
Eligibility
18 Years to 80 Years
Enrollment
330 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2024 – 2028
U.S. locations
15
States / cities
Phoenix, Arizona • Fayetteville, Arkansas • Washington D.C., District of Columbia + 12 more
Source: ClinicalTrials.gov public record
Updated Oct 30, 2025 · Synced Sep 2, 2026, 7:17 AM EDT
Completed Phase 4 Interventional Results available

Biomarker Study of Acamprosate in Schizophrenia

NCT00688324
View directory record Official record
Conditions
Schizophrenia, Schizoaffective Disorder
Interventions
Acamprosate
Drug
Lead sponsor
University of Maryland, Baltimore
Other
Eligibility
18 Years to 55 Years
Enrollment
36 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2008 – 2012
U.S. locations
4
States / cities
Baltimore, Maryland
Source: ClinicalTrials.gov public record
Updated Sep 24, 2019 · Synced Sep 2, 2026, 7:17 AM EDT
Completed No phase listed Observational

Acamprosate: Genes Associated With Response

NCT00662571
View directory record Official record
Conditions
Alcoholism
Interventions
acamprosate
Drug
Lead sponsor
Mayo Clinic
Other
Eligibility
18 Years to 80 Years
Enrollment
485 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2008 – 2013
U.S. locations
1
States / cities
Rochester, Minnesota
Source: ClinicalTrials.gov public record
Updated Mar 21, 2013 · Synced Sep 2, 2026, 7:17 AM EDT
Recruiting Phase 2 Interventional

Integrated Therapies for Alcohol Use in Alcohol-associated Liver Disease (ITAALD) Trial

NCT07060638
View directory record Official record
Conditions
Alcohol-associated Hepatitis
Interventions
IL-22, Prednisone, Acamprosate, Prednisone placebo, IL-22 (F-652) Placebo, Motivational Interviewing (MI), Motivational Enhancement Therapy (MET), Usual Care
Drug · Behavioral
Lead sponsor
Samer Gawrieh
Other
Eligibility
18 Years to 70 Years
Enrollment
216 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2026 – 2029
U.S. locations
6
States / cities
Indianapolis, Indiana • Louisville, Kentucky • Rochester, Minnesota + 3 more
Source: ClinicalTrials.gov public record
Updated Jul 14, 2026 · Synced Sep 2, 2026, 7:17 AM EDT
Completed Phase 2 Interventional

Acamprosate Treatment: Mechanisms of Action

NCT00004552
View directory record Official record
Conditions
Alcoholism
Interventions
acamprosate (Campral)
Drug
Lead sponsor
Yale University
Other
Eligibility
21 Years to 55 Years
Enrollment
120 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
Ends 2002
U.S. locations
1
States / cities
New Haven, Connecticut
Source: ClinicalTrials.gov public record
Updated Jul 1, 2015 · Synced Sep 2, 2026, 7:17 AM EDT
Terminated No phase listed Observational

Promoting Medications for Alcohol Use Disorder on the General Medicine Service

NCT04287790
View directory record Official record
Conditions
Alcohol Use Disorder
Interventions
audit and feedback, educational meetings, and academic detailing to promote medication receipt, Acamprosate, naltrexone, or disulfiram
Behavioral · Drug
Lead sponsor
Yale University
Other
Eligibility
Not listed
Enrollment
67 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2020 – 2021
U.S. locations
1
States / cities
New Haven, Connecticut
Source: ClinicalTrials.gov public record
Updated May 10, 2022 · Synced Sep 2, 2026, 7:17 AM EDT
Completed Phase 1 Interventional

Study of Acamprosate in Autism

NCT01813318
View directory record Official record
Conditions
Autistic Disorder
Interventions
Acamprosate, Placebo
Drug
Lead sponsor
Children's Hospital Medical Center, Cincinnati
Other
Eligibility
5 Years to 17 Years
Enrollment
36 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2013 – 2017
U.S. locations
1
States / cities
Cincinnati, Ohio
Source: ClinicalTrials.gov public record
Updated Feb 2, 2021 · Synced Sep 2, 2026, 7:17 AM EDT